Chinese (SSE) Market Analysis & Valuation

Market Valuation and Performance

Has the Chinese Market valuation changed over the past few years?

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Wed, 05 Aug 2026	CN¥96.8t	CN¥53.7t	CN¥3.1t	40.8x	31x	1.8x
Fri, 03 Jul 2026	CN¥102.8t	CN¥53.5t	CN¥3.1t	45.3x	33.5x	1.9x
Sun, 31 May 2026	CN¥102.4t	CN¥53.4t	CN¥3.1t	47.6x	33.5x	1.9x
Tue, 28 Apr 2026	CN¥100.9t	CN¥53.1t	CN¥3.1t	49.2x	33.1x	1.9x
Thu, 26 Mar 2026	CN¥94.7t	CN¥53.1t	CN¥3.1t	45.3x	30.9x	1.8x
Sat, 21 Feb 2026	CN¥98.8t	CN¥52.5t	CN¥3.0t	48.7x	32.9x	1.9x
Mon, 19 Jan 2026	CN¥98.7t	CN¥52.5t	CN¥3.0t	48.4x	33x	1.9x
Wed, 17 Dec 2025	CN¥89.4t	CN¥52.3t	CN¥3.0t	42.4x	30x	1.7x
Fri, 14 Nov 2025	CN¥93.2t	CN¥52.3t	CN¥3.0t	45.2x	31.3x	1.8x
Sun, 12 Oct 2025	CN¥90.5t	CN¥51.3t	CN¥2.8t	45.6x	32.5x	1.8x
Tue, 09 Sep 2025	CN¥86.3t	CN¥50.6t	CN¥2.7t	44.9x	31.8x	1.7x
Thu, 07 Aug 2025	CN¥80.1t	CN¥50.4t	CN¥2.7t	43.1x	29.3x	1.6x
Sat, 05 Jul 2025	CN¥74.7t	CN¥50.3t	CN¥2.7t	39.4x	27.9x	1.5x
Mon, 02 Jun 2025	CN¥71.5t	CN¥50.3t	CN¥2.7t	37.6x	26.8x	1.4x
Wed, 30 Apr 2025	CN¥69.7t	CN¥50.6t	CN¥2.8t	36.8x	25.2x	1.4x
Fri, 28 Mar 2025	CN¥73.2t	CN¥50.3t	CN¥2.8t	38.2x	26.4x	1.5x
Sun, 23 Feb 2025	CN¥74.1t	CN¥50.4t	CN¥2.9t	38.1x	25.5x	1.5x
Tue, 21 Jan 2025	CN¥69.6t	CN¥50.1t	CN¥2.7t	34.8x	25.4x	1.4x
Thu, 19 Dec 2024	CN¥72.7t	CN¥49.9t	CN¥2.7t	36.2x	26.7x	1.5x
Sat, 16 Nov 2024	CN¥71.9t	CN¥49.9t	CN¥2.7t	35.1x	26.4x	1.4x
Mon, 14 Oct 2024	CN¥67.1t	CN¥50.3t	CN¥2.8t	31.5x	24.2x	1.3x
Wed, 11 Sep 2024	CN¥55.4t	CN¥50.3t	CN¥2.8t	26.8x	20x	1.1x
Fri, 09 Aug 2024	CN¥58.2t	CN¥50.7t	CN¥2.8t	27.7x	20.6x	1.1x
Sun, 07 Jul 2024	CN¥59.2t	CN¥50.8t	CN¥2.8t	28x	21.1x	1.2x
Tue, 04 Jun 2024	CN¥63.7t	CN¥50.7t	CN¥2.8t	30.7x	22.8x	1.3x
Thu, 02 May 2024	CN¥64.9t	CN¥50.9t	CN¥2.8t	32x	23.2x	1.3x
Sat, 30 Mar 2024	CN¥64.1t	CN¥51.0t	CN¥2.9t	30.8x	22.3x	1.3x
Mon, 26 Feb 2024	CN¥62.3t	CN¥51.2t	CN¥2.8t	29.5x	21.9x	1.2x
Wed, 24 Jan 2024	CN¥59.7t	CN¥52.3t	CN¥3.2t	29.9x	18.8x	1.1x
Fri, 22 Dec 2023	CN¥64.1t	CN¥49.8t	CN¥2.7t	34.5x	23.6x	1.3x
Sun, 19 Nov 2023	CN¥67.4t	CN¥49.8t	CN¥2.7t	36.2x	24.9x	1.4x
Tue, 17 Oct 2023	CN¥67.2t	CN¥49.6t	CN¥2.7t	34.8x	24.6x	1.4x
Thu, 14 Sep 2023	CN¥68.0t	CN¥49.6t	CN¥2.7t	34.9x	24.9x	1.4x
Sat, 12 Aug 2023	CN¥70.0t	CN¥49.3t	CN¥2.8t	34.9x	24.7x	1.4x

Current Market PE

Investors are optimistic on the Chinese market, and appear confident in strong long term growth rates.

The market is trading at a PE ratio of 31.0x which is higher than its 3-year average PE of 26.7x.

Past Earnings Growth

The earnings for Chinese listed companies have grown 3.3% per year over the last three years.
Revenues for these companies have grown 2.9% per year.
This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Sector Trends

Which sectors have driven the changes within the Chinese Market?


CN Market	2.60%
Telecom	10.59%
Consumer Discretionary	4.01%
Industrials	3.14%
Healthcare	2.83%
Real Estate	2.69%
Tech	2.54%
Materials	2.42%
Energy	1.84%
Consumer Staples	1.65%
Utilities	0.82%
Financials	0.75%

Sector PE

Investors favour the Tech sector the most for future growth, which is trading above its 3-year average PE ratio of 84.6x.

The market's confidence is likely because analysts are expecting annual earnings growth of 38.0%, which is higher than its past year's earnings growth of 5.2% per year.

Forecasted Growth

Analysts are most optimistic on the Real Estate sector, expecting annual earnings growth of 40% over the next 5 years.
This is better than its past earnings decline of 3.1% per year.

In contrast, the Financials sector is expected to see its earnings grow by 8.6% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

Company	Last Price	7D	1Y	Valuation	Sector
601138 Foxconn Industrial Internet	CN¥65.92	14.1% +CN¥162.1b	92.2%	PE32.2x	Tech
688825 CXMT	CN¥54.30	2.5% +CN¥90.3b	n/a	PE128.8x	Tech
603259 WuXi AppTec	CN¥147.50	16.6% +CN¥61.7b	57.6%	PE21.1x	Healthcare
601899 Zijin Mining Group	CN¥34.10	6.1% +CN¥51.5b	69.1%	PE14.6x	Materials
300750 Contemporary Amperex Technology	CN¥405.20	2.1% +CN¥38.4b	52.9%	PE21.9x	Industrials

Company

Last Price

Valuation

Sector

601138 Foxconn Industrial Internet

CN¥65.92

14.1%
+CN¥162.1b

92.2%

PE32.2x

Tech

688825 CXMT

CN¥54.30

2.5%
+CN¥90.3b

n/a

PE128.8x

Tech

603259 WuXi AppTec

CN¥147.50

16.6%
+CN¥61.7b

57.6%

PE21.1x

Healthcare

601899 Zijin Mining Group

CN¥34.10

6.1%
+CN¥51.5b

69.1%

PE14.6x

Materials

300750 Contemporary Amperex Technology

CN¥405.20

2.1%
+CN¥38.4b

52.9%

PE21.9x

Industrials

Sichuan Biokin Pharmaceutical Co., Ltd. Announces Second Approval of Iza-Bren in China for the Treatment of Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

SystImmune announced that its parent company, Sichuan Biokin Pharmaceutical Co. Ltd., has received regulatory approval from China's National Medical Products Administration (NMPA) for iza-bren (izalontamab brengitecan) for the treatment of adult patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC) whose disease has progressed following prior platinum-based chemotherapy and PD-1/PD-L1 inhibitor therapy. This marks the second approved indication for iza-bren in China following its recent approval for recurrent or metastatic nasopharyngeal carcinoma (NPC), further establishing iza-bren as a first-in-class EGFR × HER3 bispecific antibody-drug conjugate (ADC) with broad clinical potential across multiple solid tumors. The approval is supported by results from the pivotal PANKU-Esophagus01 (BL-B01D1-305) study. The study met both dual primary endpoints of progression-free survival (PFS) and overall survival (OS), demonstrating statistically significant and clinically meaningful improvements versus chemotherapy, while maintaining a manageable safety profile. The results were previously presented during an oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Key results from the PANKU-Esophagus01 study included: Median overall survival of 9.8 months with iza-bren versus 7.2 months with chemotherapy (HR=0.64, 95% CI: 0.49–0.83; p=0.0004). Median progression-free survival by BICR of 4.2 months with iza-bren versus 2.0 months with chemotherapy (HR:0.50; 95% CI: 0.40-0.63; pAbout PANKU-Esophagus01. PANKU-Esophagus01 (BL-B01D1-305) is a randomized, open-label, multicenter phase 3 clinical trial evaluating iza-bren versus investigator's choice chemotherapy in patients with recurrent or metastatic esophageal squamous cell carcinoma who experienced disease progression following platinum-based chemotherapy plus PD-1/PD-L1 inhibitor therapy. A total of 497 patients were randomized across 80 study centers in China. The study met both dual primary endpoints of progression-free survival and overall survival at the pre-specified interim analysis. Esophageal cancer is the seventh most commonly diagnosed cancer and the sixth leading cause of cancer-related death worldwide. Esophageal squamous cell carcinoma (ESCC) is the predominant histologic subtype globally and accounts for approximately 90% of esophageal cancer cases in China. Despite advances in first-line treatment with platinum-based chemotherapy combined with PD-1/PD-L1 inhibitors, most patients with recurrent or metastatic ESCC ultimately experience disease progression and have historically faced limited treatment options in the second-line setting, with poor response rates and a median overall survival of less than one year. SystImmune, in collaboration with BMS outside of China, is developing iza-bren (BL-B01D1), a bispecific antibody-drug conjugate (ADC) that targets both EGFR and HER3, which are highly expressed in various epithelial cancers and are known to be associated with cancer cell proliferation and survival. Iza-bren's dual mechanism of action blocks EGFR and HER3 signals to cancer cells, reducing proliferation and survival signals. In addition, upon antibody mediated internalization, iza-bren's therapeutic novel Topo1i payload is released causing cytotoxic stress that leads to cancer cell death.

Chinese (SSE) Market Analysis & Valuation

Market Valuation and Performance

Sector Trends

Top Stock Gainers and Losers

Market Insights

What does frontier-beating open source mean for AI investors?

Latest News

Chaozhou Three-Circle (Group) Co., Ltd. Announces Board and Committee Changes

Wuxi Apptec Co., Ltd. Raises Full Year Guidance for the Fiscal Year 2026

Eastroc Beverage (Group) Co., Ltd. Announces an Interim Ordinary Dividend for the Six Months Ended 30 June 2026

Contemporary Amperex Technology Co., Limited Proposes Interim Cash Dividend for the First Half of 2026

China Merchants Bank Co., Ltd. Announces Appointment of Wang Xiaoqing as President, Effective July 28, 2026

Now 23% undervalued after recent price drop

Foxconn Industrial Internet Co., Ltd. (SHSE:601138) announces an Equity Buyback for CNY 2,000 million worth of its shares.

Less than half of directors are independent

Investor sentiment deteriorates as stock falls 17%

Sichuan Biokin Pharmaceutical Co., Ltd. Announces Second Approval of Iza-Bren in China for the Treatment of Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Dividend of CN¥0.14 announced

Investor sentiment improves as stock rises 21%

Dividend of CN¥0.79 announced

Zijin Mining Group Company Limited Provides Earnings Guidance for the Six Months Ended 30 June 2026

Kweichow Moutai Co., Ltd. to Report First Half, 2026 Results on Aug 15, 2026

Guotai Haitong Securities Co., Ltd. to Report First Half, 2026 Results on Aug 19, 2026